SGLT2 inhibitors have proven to be effective in preventing CKD progression, and recent American Diabetes Association guidelines were updated to recommend SGLT2 inhibitors to delay CKD progression in patients with CKD ≥3 [27]. This evidence concerns the gene SLC5A2 and diabetes mellitus.